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One Sentence Summary: Crohn’s disease associated frameshift mutation in CSF2RB 
results in decreased STAT5 activation in a dominant negative manner.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Author contributions: C.L-S, V.N., P.I., and C.JH. design this study, and contributed in 
writing, interpretation of data and quality assessment. H.KY. performed all the genetic 
statistical analysis and contributed in study design, writing, and quality assessment. 
B.SR. and M.DP. contributed in study design, interpretation of data, and quality 
assessment. D.MJ. contributed in study design, statistical analysis, and interpretation of 
data. R.JI., D.RJ., A.MT., A.G., P.I., K.S., H.H., M.JL., L.T., D.A., P.V. and S.MS. 
contributed in study design and quality assessment. M.A., R.A., H.NY., S.AW., and 
M.M. contributed in study design and interpretation of data. H.T., L.S., and Z.H. 
statistical analysis and quality assessment. L.AP. contributed in statistical analysis and 
interpretation of data. A.C. contributed in writing and quality assessment. R.R. and C.S. 
contributed in study design. L.D., R.M., S.ER., G.A., B.BM., and N.K. contributed in 
statistical analysis. M.AM. contributed in interpretation of data. N.SE., Z.W., F.J-A., L.T., 
F-H. H., S.LP., S.Y., L.P., G.J., K.A., S.B., S.JM., D.LW., K.S., C.AS., B.N., P.N., D.MJ., 
T.S., T.K., and S.EJ. contributed in data quality assessment. 
 
Funding source: The NIH (DK092235), Inflammatory Bowel Disease Genetics 
Consortium (DK062429), Genetic Research Center at the Icahn School of Medicine 
(DK062422), New York Crohn’s Foundation, Consortium ancillary RO1 (DK099097), 
U01 (DK062431), Inflammatory Bowel Disease Genetic Research Chair, RO1 
(DK062420), RO1 (CA141743), the Atran Foundation and the Sanford J. Grossman 
Charitable Trust financially supported this work. Researchers at UCL were funded by 
the Wellcome Trust, Charles Wolfson Charitable Trust, and the Irwin Joffe Memorial 
Fellowship. IBD Research at Cedars-Sinai is supported by USPHS grant PO1 
(DK046763) and the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and 
Immunobiology Research Institute Research Funds. Project investigators  are 
supported by The Helmsley Charitable Trust (D.P.B.M.), The European Union 
(D.P.B.M.), The Crohn's and Colitis Foundation of America (CCFA) (D.P.B.M.), The 
Joshua L. and Lisa Z. Greer Chair in IBD Genetics (D.P.B.M.), and grants, DK062413, 
DK046763-19, AI067068, HS021747 (D.P.B.M.).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract:  
Background & Aims: Crohn’s disease (CD) has the highest prevalence in Ashkenazi 
Jewish populations. We sought to identify rare, CD-associated frameshift variants of 
high functional and statistical effects.  
 
Methods: We performed exome-sequencing and array-based genotype analyses of 
1477 Ashkenazi Jewish individuals with CD and 2614 Ashkenazi Jewish individuals 
without CD (controls). To validate our findings, we performed genotype analyses of an 
additional 1515 CD cases and 7052 controls for frameshift mutations in the colony 
stimulating factor 2 receptor beta common subunit gene (CSF2RB). Intestinal tissues 
and blood samples were collected from patients with CD; lamina propria leukocytes 
were isolated and expression of CSF2RB and GMCSF-responsive cells were defined by 
mass cytometry (CyTOF analysis). Variants of CSF2RB were transfected into HEK293 
cells and expression and functions of gene products were compared.  
 
 
Results: In the discovery cohort, we associated CD with a frameshift mutation in 
CSF2RB (P=8.52x10–4); the finding was validated in the replication cohort (combined 
P=3.42x10–6). Incubation of intestinal lamina propria leukocytes with GMCSF resulted 
in high levels of phosphorylation of STAT5 and lesser increases in phosphorylation of 
ERK and AKT. Cells co-transfected with full-length and mutant forms of CSF2RB had 
reduced pSTAT5 following stimulation with GMCSF, compared to cells transfected with 
control CSF2RB, indicating a dominant negative effect of the mutant gene. Monocytes 
from patients with CD who were heterozygous for the frameshift mutation (6% of CD 
cases analyzed) had reduced responses to GMCSF and markedly decreased activity of 
aldehyde dehydrogenase; activity of this enzyme has been associated with immune 
tolerance. 
 
Conclusions: In a genetic analysis of Ashkenazi Jewish individuals, we associated CD 
with a frameshift mutation in CSF2RB. Intestinal monocytes from carriers of this 
mutation had reduced responses to GMCSF, providing an additional mechanism for 
alterations to the innate immune response in individuals with CD. 
 
KEY WORDS: IBD, inflammatory bowel disease; risk factor; ethnic variation 
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Background and Aims  
Genome-wide association studies (GWAS) have identified over 200 loci associated with 
inflammatory bowel disease (IBD), largely represented by common variants of modest 
effect. Taken together, these loci account for 13.1% and 8.2% of the phenotypic 
variance for Crohn’s disease (CD) and ulcerative colitis (UC), respectively1. For only 10-
15% of these loci, the maximally associated marker is predicted to cause a protein-
coding change2; most association signals are believed to be driven by genetic 
polymorphisms which modulate gene expression, often in subtle and context-specific 
ways.  
 
The large majority of IBD loci confers risk to both CD and UC and implicates numerous 
pro- and anti-inflammatory pathways (e.g. interleukin 23, prostaglandins, interleukin 10) 
and immune cell subsets1, 2. As with many chronic immune-mediated diseases, in 
ulcerative colitis, the most significant association is to the major histocompatibility 
complex (MHC), specifically class II alleles. In marked contrast, MHC associations are 
not dominant in European ancestry CD; rather, protein-coding polymorphisms in the 
NOD2 (nucleotide oligomerization domain 2) gene and autophagy pathways (e.g. 
ATG16L1) involved in innate immunity represent major association signals. The NOD2 
associations confer the largest statistical effects (i.e. odds ratios) observed in IBD2; 
most prominent among these is a cytosine insertion, resulting in a frameshift mutation3, 4 
which results in impaired innate immunity, specifically a complete loss of response to 
microbial stimuli (e.g. bacterial peptidoglycan)5. CD-associated NOD2 risk alleles are 
relatively uncommon, with allele frequencies in controls of less than 5%; therefore, only 
a minority of CD patients carry NOD2 risk alleles. Taken together, these findings 
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established that a significant fraction of CD patients have impaired innate immune 
function, that is, impaired response to microbial stimulation with NOD2 risk allele 
carriage.  
 
The extent to which ‘Mendelian-like’, rare protein-coding mutations with greater 
statistical and functional effects contribute to complex human disease is currently 
unknown. Compared to common variants, there is decreased power to detect 
association with rare variants6.  Furthermore, rare insertion-deletion frameshift 
mutations are under-represented in commercially available genotyping chips due to 
suboptimal design features. Finally, the elucidation of rare disease associated variants 
may be hindered by their greater population specificity. Of particular interest here, the 
Ashkenazi Jewish (AJ) population has a 4-7 fold higher prevalence of CD7, 8. As a 
founder population, genetic analyses of Jewish populations have identified numerous 
mutations unique to the Ashkenazim, contributing to a wide-array of Mendelian 
diseases9. Importantly, while such uncommon risk alleles may be more identifiable in AJ 
populations, they can highlight pathways of broad significance. For example, the I1307K 
polymorphism in the APC (adenomatous polyposis coli) gene has a carrier rate of 6.1% 
in AJ populations and confers an odds ratio of 1.9 fold for colorectal cancer (CRC)10. 
While this specific variant is uniquely observed in AJ populations, the APC pathway is of 
broad significance in CRC pathogenesis, both in the form of extremely rare, highly 
penetrant APC mutations associated with the familial adenomatous polyposis 
syndrome, as well as somatic mutations in sporadic CRC11.  
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In this study, we sought to identify AJ specific or predominant rare mutations of high 
functional effects, with a particular focus on insertion-deletion variants, which result in 
frameshift changes. We performed exome sequencing of AJ CD cases, and genotyped 
224 frameshift variants using custom array genotyping in an AJ case-control cohort. 
Beyond the NOD2 frameshift, the most significantly associated frameshift mutation was 
observed in CSF2RB, the beta-chain receptor for the GM-CSF, IL-3 and IL-5 cytokines. 
This association was strongly replicated in an independent case-control cohort. We 
observe a marked decrease in GM-CSF signaling in monocytes from heterozygous 
frameshift carriers, further implicating innate immune deficiencies in the pathogenesis of 
CD.  Our study highlights the value of the AJ population in identifying disease-
associated coding region polymorphisms of high statistical and functional effects in 
complex diseases and further implicates impaired innate immunity in CD pathogenesis.  
Methods  
 
Human subjects  
Written informed consent for genetic analyses was obtained from all subjects through 
the respective Institutional Review Boards from the contributing institutions 
(Supplemental table 1). Resected terminal ileal tissues and blood samples from Crohn’s 
patients were obtained after written informed consent under the guidelines of the 
Human Investigations Committee (IRB) of the Icahn School of Medicine at Mount Sinai. 
IBD patients had diagnoses confirmed at each recruiting site by a health care provider, 
based on standard criteria including clinical presentation, as well as endoscopic, 
radiologic and/or pathologic confirmation.  
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Genetic analysis 
We conducted exome sequencing on 47 AJ CD patients and 3 controls with full AJ 
ancestry as confirmed by GWAS principal component analysis (PCA). Exome capture 
was performed using the Agilent SureSelect library and sequencing performed using 
paired-end 75-bp reads with the Illumina GAII. Sequence reads were mapped to the 
reference genome (hg18) using the BWA program using default parameters12, and 
coordinates were translated to the hg19 reference genome using LiftOver in the UCSC 
Genome Browser with default parameters13. The Genome Analysis Toolkit (GATK) v2 
was used to call alleles at variant sites14. For the discovery case-control association 
study, a total of 7,813 individuals with Crohn’s disease and 8,781 unaffected controls, of 
which 1,908 and 2,955 have Jewish ancestry, respectively, were enrolled in this study at 
centers throughout North America, Europe, and Israel. 
 
Markers identified by exome sequencing not present on the Illumina HumanExome 
Beadchip and passing design feature filters were added. Genotyping data were 
generated at three genotyping centers (Philadelphia, PA, Manhasset, NY, and Los 
Angeles, CA) using the same custom genotyping array. The data were combined and 
preliminary genotypes were called jointly using input from all three centers in 
GenomeStudio. Following guidelines produced by the Cohorts for Heart and Aging 
Research in Genome Epidemiology (CHARGE) consortium, we enforced quality control 
using SNP metrics based on fluorescent probe intensities and genotype frequencies, as 
well as visual inspection of markers with uncertain genotyping quality15.  
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Following manual review, additional quality thresholds for sample exclusion (genotype 
call rate < 0.968, p50GC < 0.758, or average heterozygosity > 0.31) were applied. 
Related samples were identified using pairwise identity-by-descent detection in PLINK16 
and a minimum necessary set of individuals was removed to yield a cohort without first- 
or second-degree genetic relationships. Samples with discrepancy between self-
reported gender and genotypic gender were excluded. Following association analysis, 
cluster plots of the frameshift mutations were re-examined to ensure high-quality 
genotype calling.  
 
We created a set of 10,312 null independent autosomal polymorphisms by removing 
markers with pairwise linkage disequilibrium (LD) of r2 > 0.05, those with minor allele 
frequency (MAF) below 0.05, custom content, and variants within established IBD loci. 
PCA was performed using the principal component function in R version 2.15.1 
(Supplemental figure 1). The PCA was conducted on our dataset in conjunction with a 
reference cohort of non-Jewish European-ancestry samples on which exome chip data 
was available. Using membership in the PCA cluster as genetic validation of AJ 
ancestry (Supplemental figure 1, red dots), we conducted all further analyses using only 
samples with 100% AJ ancestry: 1,477 CD cases and 2,614 independent healthy 
controls (Table 1).  
 
For the exome sequencing experiment, we performed power calculations using binomial 
distribution probability estimates, in order to assess the proportion of variation in the 
genome captured in our study (Supplemental table 2). We also calculated power 
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estimates for the Discovery Phase association testing using cumulative probability 
densities under a normal distribution.  
 
To corroborate discovery findings, single-point genetic association was done with an 
independent AJ replication cohort containing 1,515 CD cases and 7,052 healthy 
controls. Ashkenazi Jewish ancestry was validated for all samples by principal 
components analysis using genome-wide variation. Association testing was conducted 
using Χ2 tests; pooled analyses were performed on the summed allele counts of both 
the Discovery and Replication Phase genotypes (Table 1). 
 
Single cell suspensions from ileal resection tissues  
Resection specimens were washed in HBSS (Life Technologies 14170112) and then 
incubated in HBSS (Ca2+ and Mg2+ free) with 1mM 2-mercaptoethanol (Millipore es-
007e) for 10 min at room temperature. Samples were transferred to HBSS (Ca2+ and 
Mg2+ free) with 5mM EDTA and 10mM HEPES buffer (Life Technologies 15630080) for 
20 min in 37 °C shaker, minced and placed in HBSS ( Ca2+ and Mg2+) with 2% heat-
inactivated (HI) FBS, Collagenase (Sigma C5138) and DNase I (Sigma DN25) for 30 
min into a shaker set at 100 rpm and 37 °C. The sol ution was vortexed and filtered 
through a 70-micron filter. Single cell suspension was centrifuged and lamina propria 
leukocytes were collected by a 40%:80% Ficoll gradient for 20min at 2500 rpm and 
20°C. Lamina propria leukocytes were collected at t he interphase and washed with 
FACS buffer (PBS containing 2% HI-FBS and 5mM EDTA). Cells were labeled with 5µM 
cisplatin for 2 minutes to identify dead cells (Fienberg HG, Cytometry Part A, 2012) and 
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live cells counts were determined using a Neubauer counting chamber and a light 
microscope. Half of the cells were treated with 10 ng/ml GM-CSF for 15 minutes, while 
the other half were left unstimulated. All cells were then fixed with 1.6% formaldehyde 
for 20 minutes on ice and processed for Flow Cytometry and CyTOF analysis. 
CyTOF analysis 
All mass cytometry reagents were purchased from Fluidigm Inc. (formerly DVS 
Sciences) unless otherwise noted. Stimulated and non-stimulated cell suspensions 
were first barcoded using unique combinations of CD45 antibodies conjugated to 
distinct isotopes. The barcoded samples were then pooled and stained with a panel of 
antibodies against cell surface markers (Supplemental table 3) for 30 minutes on ice, 
then washed, permeabilized with ice-cold 100% methanol, and stained with antibodies 
against intracellular phospho-protein epitopes (Supplemental table 3). After antibody 
staining, the cells were washed and incubated in 1.6% formaldehyde with 125nM 
nucleic acid Ir-intercalator to label all nucleated cells. Immediately prior to acquisition, 
the cells were washed in PBS, then in distilled water and resuspended in distilled water 
containing a 1/20 dilution of EQ 4 Element Normalization beads. The samples were 
acquired on a CyTOF2 following routine instrument tuning and optimization. The 
resulting FCS files were normalized and concatenated using CyTOF acquisition 
software and uploaded to Cytobank17  for analysis. FCS files were manually pre-gated 
to exclude EQ beads, cell debris, cell doublets and dead cells, and the resulting live 
CD45+ population was clustered (Table S3, clustering markers designated in blue) 
using SPADE18. Putative populations were identified on the basis of multidimensional 
marker coexpression. Population frequencies were calculated as a percentage of total 
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CD45+ events, and population distributions of CSF2RA (CD116) and CSF2RB (CD131) 
were determined for each population, normalized to non-stained controls for the 
corresponding mass channels. Phospho-STAT5, -AKT and -ERK expression was 
normalized to non-stained controls for the corresponding mass channel and expressed 
as a fold change between GM-CSF stimulated samples and non-stimulated controls. 
The Cytof data for phosphorylated STAT5 are normally distributed, thus the P values 
were calculated with two sample t tests having equal variance. Other P values were 
generated with the non-parametric Wilcoxon rank sum test. 
Clone construction and transfection studies  
The complete coding regions of CSF2RA, CSF2RB_WT and CSF2RB_Mut were 
synthesized by GeneArt gene synthesis and cloned into the Gateway pDONR™221 
Vector (GeneArt, Life Technologies), and the clone sequences confirmed by Sanger 
sequencing. For immunoblot analyses, CSF2RB_WT and Mut were sub-cloned into the 
Gateway destination vector pcDNA6.2_C-EmGFP-DEST (Life-Technologies), and 
CSF2RA into pcDNA6.2_C-YFP-DEST (Life-Technologies). For co-localization studies, 
CSF2RA and CSF2RB_WT were sub-cloned into PCDNA6.2/V5-DEST (Life-
technologies) and pDEST-mcherry-N1 (Addgene plasmid # 31907), respectively. 
 
HEK293 cells (ATCC CRL 1573) were seeded at 2x105 cells per well in 24 well plates 
and transfected with 500ng of total DNA with Lipofectamine 3000 (Life Technologies). 
Transfected DNA was comprised of combinations of pcDNA6.2_C-YFP-DEST -
CSF2RA, pcDNA6.2_C-EmGFP-DEST-CSF2RB_WT, and pcDNA6.2_C-EmGFP-
DEST-CSF2RB_Mut (Life Technologies). Twenty-four hours post-transfection, cells 
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were stimulated with 0, 0.4, 2 or 10 ng/ml of GM-CSF for 15 min and lysed in RIPA 
buffer (Millipore). For co-localization studies, CSF2RA, CSF2RB_WT and CSF2RB_Mut 
were co-transfected and stimulated with GM-CSF (10 ng/ml). 
Immunoblotting and confocal analysis  
Total protein samples of transfected HEK293 or isolated human monocytes were 
prepared for SDS-PAGE.  From each sample, 10-25 µg of protein was separated on a 
Mini-Protean TGX 4-15% (Bio-Rad) gel and transferred to a PVDF membrane using a 
Bio-Rad electrophoretic transfer apparatus (Trans-Blot Turbo, Bio-Rad).  After blocking 
with 5% BSA, the membrane was probed with either of the following primary antibodies: 
a 1:1000 GFP (Abcam ab1218), 1:10000 dilution of Actin (Sigma A5441), 1:500 of 
STAT5 (Santa Cruz sc-835), 1:1000 of pSTAT5 (Cell Signaling 4322), 1:1000 of 
pERK1/2 (Cell Signaling 9101) and 1:1000 of pAKT (Cell Signaling 4058). A secondary 
incubation of either 1: 40000 dilution of horseradish peroxidase (HRP) conjugated goat 
anti-mouse or 1:20000 dilution goat anti-rabbit secondary antibody was applied to the 
membrane. The immunoblots were developed with SuperSignal West Pico (Life 
Technologies) and band intensities were quantified through ImageJ and the fold-change 
normalized to no GM-CSF treatment.  
 
HEK293 cells were plated on glass coverslips (Electron Microscopy Sciences) and co-
transfected with CSF2RA, CSF2RB_WT and CSF2RB_Mut plasmids as previously 
described.  Cells were fixed with 2% paraformaldehyde PBS solution (Sigma), and 
incubated with rabbit anti-CSF2RB C-terminal antibody (Santa cruz: sc-376582) at 
1:200 dilution in blocking solution (0.6% saponin, 5% fetal calf serum, PBS pH7.4) at 
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room temperature for 1 hour, and followed by Alexa 555 conjugated goat anti-rabbit 
secondary antibody (Life technologies) at 1:500 dilution in blocking solution at room 
temperature for 1 hour. All imaging was performed on a Zeiss LSM510META confocal 
laser scanning confocal microscope (Carl Zeiss, USA) equipped with 488nm and 565 
nm laser line and 63X oil immersion objectives with 1.4 numerical aperture (NA). 
ALDEFLUOR activity measurement and flow cytometry 
Isolated monocytes were plated at 2x106 in 2ml complete RPMI (Gibco) in a 24 well 
plate (Corning) and cultured for 7 days at 37oC and 5% CO2. Fifty percent of the cell 
culture media was replaced with fresh media containing GM-CSF (10ng/ml, Peprotech) 
and MCSF (50ng/ml, Peprotech). On day 7, cells were harvested and washed with ice 
cold PBS. Cultured monocytes were stained with the ALDEFLUOR KIT (Stem cell 
technologies) according to the manufacturer’s protocol. After washing, cells were 
stained with CD11c (BD Horizon, B-ly6) and CD14 (Invitrogen) and analyzed on an LSR 
Fortessa II (BD). FCS files were analyzed using FlowJo software. 
 
For intracellular staining, surface stained cells were fixed for 20 minutes on ice using the 
BD Cytofix/Cytoperm kit (BD Biosciences). Intracellular staining with human CD131-Pe 
antibody was performed using Perm/wash Solution (BD Biosciences). Cells were 
analyzed on a BD Fortessa II (BD Biosciences). 
 
Monocytes isolation from CSF2RB frameshift mutation carriers 
Experiments were performed with monocytes from three pairs of CD patients, each time 
including a CSF2RB frameshift carrier and a non-carrier. The carrier and control pair 
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were matched based on gender and age, within a +/- ten year gap. The five tubes of 
blood were drawn in 10mL sodium heparin tubes within one hour between carrier and 
control patients. PBMCs were obtained from blood through a density gradient 
centrifugation with Ficoll-Paque Plus (GE) and Leucosep tubes. Monocytes were 
isolated from PBMCs with the Monocyte Isolation Kit II (Miltenyi) according to company 
protocol. Negatively selected cells were plated at 1x106 cells per well in 24 well plates. 
For short-term studies, monocytes were kept in RPMI 1640 (Life Technologies) 
overnight, stimulated with GM-CSF for 15 min, and lysed in RIPA buffer. Monocytes for 
7-day studies were cultured in RPMI 1640, 10% fetal bovine serum, 10 ng/ml MCSF, 
and either 0, 0.4, 2 or 10 ng/ml of GM-CSF.  Media were collected and replaced at 24, 
72, and 120 hours.    
 
Results  
 
Exome sequencing and association studies  
Exome sequencing detected a total of 371 frameshift mutations in 47 CD patients and 3 
controls having full AJ ancestry19. Of these, 224 mutations passed the Illumina design 
filters for custom content and were added to the HumanExome beadchip. Using this 
array, we performed association analyses in 1,477 unrelated CD cases, and 2,614 
independent healthy controls passing quality filters, with full AJ ancestry genetically 
validated using PCA (discovery cohort). Sequencing 94 independent chromosomes 
would have 0.39, 0.62 and 0.77 statistical power to identify variants of 0.005, 0.01 and 
0.015 minor allele frequencies, respectively (Supplemental table 2). Given the size of 
our discovery association cohort (Table 1), we would have reasonable power under a 
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range of effect sizes (i.e., odds ratios) to detect nominal association (P value < 0.001) 
for variants having minor allele frequencies of 0.01 and 0.015 (Supplemental table 2). 
Increasingly rarer variants have progressively decreasing power to detect association; 
below 0.005, only limited power to detect association is predicted (Supplemental table 
2). Therefore, we restricted subsequent analyses to those variants having an allele 
frequency > 0.005. Of the 224 frameshift mutations, 88 demonstrated a minor allele 
frequency of > 0.005.  
 
Quantile-quantile (Q-Q) analysis of the 88 frameshift mutations was evaluated in order 
to assess the validity of the null distribution assumption. It revealed only two markers 
demonstrating significantly greater association evidence than predicted, namely the 
NOD2 frameshift mutation and a frameshift mutation in the CSF2RB gene (P value < 
8.52 x 10-4) (Figure 1A), which encodes for the colony stimulating factor 2 receptor, beta 
chain. The CSF2RB mutation involves deletion of a single guanine base, which is 
predicted to cause a frameshift at codon 708 of CSF2RB. This would result in the 
expression of a 729-amino acid sequence, compared to 897 residues encoded by the 
canonical transcript (Figure 1B). CSF2RB encodes for the common beta-chain receptor 
for the IL-3, IL-5 and GM-CSF (granulocyte-monocyte colony stimulating factor) 
cytokines.  
 
The CSF2RB association in the discovery cohort is nominally significant, with 
Bonferroni-corrected significance of 88 markers estimated at 5.68 x 10-4. Therefore, we 
performed replication genotyping of CSF2RB in an independent case-control cohort of 
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1515 AJ CD cases and 7052 AJ controls (Table 1) and observed almost identical allele 
frequencies and odds ratios compared to the discovery cohort, with a combined P value 
of 3.42 x 10-6. While this variant is more than an order of magnitude less frequent in 
non-Jewish European ancestry compared to AJ cohorts, we observed the same 
direction of effect (i.e., frameshift mutation frequency greater in cases, 0.0022, than in 
controls, 0.0016) and similar odds ratios (1.68, P value = 0.09) in the non-Jewish cohort.  
 
CSF2RB and NOD2 are both expressed in intestinal innate immune cells, but 
demonstrate distinct patterns of expression in CyTOF-defined cell subsets  
We next sought to compare the intestinal expression of CSF2RB and NOD2 by CyTOF, 
which allows for a highly refined cellular definition from complex tissues; using 
antibodies labeled with heavy metals having minimal spectral overlap between 
neighboring isotopes, simultaneous analysis in a single panel of many proteins is 
possible. We designed a CyTOF panel that included immune cell classification markers, 
with a particular focus on innate immunity, as well as members of the GM-CSF signaling 
pathway (Supplemental table 3).  
 
While both CSF2RB and NOD2 function in innate immunity, key differences in the 
distribution of their expression are observed. Among the most prevalent cell subsets, 
while CSF2RB (Figure 2A) and NOD2 (Figure 2C) are both expressed in monocytes 
and macrophages, CSF2RB is highly expressed in eosinophils, where NOD2 
expression is nominal (n=3, P value =0.0002). Conversely, high levels of NOD2, but not 
CSF2RB expression are observed in plasma cells (n=3, P value = 0.004). NOD2 is 
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broadly expressed in monocytes, macrophages and dendritic cells (Figure 2C). In 
contrast to NOD2, more restricted expression of CSF2RB within mononuclear 
phagocytes is observed; higher expression of CSF2RB was observed specifically in 
HLA-DR high expressing monocytes from inflamed tissues (Figure 2A).  The HLA-DR 
high, CSF2RB positive monocyte population in inflamed tissue also expresses CD206, 
a marker for resident macrophages20 (Figure 2D). No expression of CSF2RB was 
observed in NK cells, T lymphocytes or B lymphocytes, and intermediate levels were 
observed in plasma cells.  
 
GM-CSF stimulation of intestinal immune cells demonstrates broad pSTAT5 induction, 
but limited pAKT and pERK induction 
Previous studies have reported that GM-CSF-deficient mice have impaired 
mononuclear effector cell function, resulting in reduced regulatory T cell numbers and 
impaired oral tolerance21. In a separate study, administration of neutralizing anti-GM-
CSF antibodies to NOD2-deficient, piroxicam-treated mice worsens ileal inflammation22. 
We therefore sought to define the signaling pathways and intestinal immune cells 
induced by GM-CSF stimulation.  
 
We observed significantly higher fractions of monocytes, macrophages and neutrophils 
in inflamed compared to non-inflamed tissue (Figure 3A). Expression patterns of 
CSF2RA by cell types largely mirrored those of CSF2RB, although expression is highly 
variable in expression between cell subtypes (Figure 3C). We observed greater 
induction of pSTAT5 compared to pAKT or pERK (Figure 3B). Specifically, within 
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inflamed tissues, we observe GM-CSF stimulated pSTAT5 induction of 2.0- and 3.0-fold 
(Figure 3B, P value = 0.034 and 0.015, respectively) in monocytes and macrophages, 
respectively, by Cytof, but no significant induction of pAKT or pERK. We corroborated 
these findings using phosphoflow cytometry in CD14+ intestinal cells, observing a 4.0-
fold induction (P value = 0.031) of pSTAT5, with no induction of pAKT nor pERK 
observed (Supplementary Figure S2). In contrast to GM-CSF stimulation, PMA-
stimulation in CD14+ intestinal cells resulted in significant induction of pAKT and pERK, 
with 2.0- and 2.6-fold induction, respectively (P values = 0.032 and 0.032, 
Supplementary Figure S2). In our Cytof analyses, cell subtypes demonstrating induction 
of pSTAT5 with GM-CSF stimulation largely mirror expression patterns of CSF2RA and 
CSF2RB; comparable induction of pSTAT5 is broadly observed, with a couple of 
exceptions (Figure 3B, 3D). Plasma cells, despite expressing both receptor subunits, do 
not demonstrate pSTAT5 induction, and neutrophils demonstrate relatively modest 
induction. No significant differences in pSTAT5 intensity were observed between 
uninflamed and inflamed tissue in GM-CSF responsive cells except monocytes (Figure 
3D). However, the estimates of pS AT5 induction are based, in some cases, on ten-fold 
fewer monocytes (Figure 3A) from non-inflamed compared to inflamed tissues, so 
estimates of pSTAT5 fold-induction are subject to greater variability.  
 
Loss–of-function, dominant negative effect of CSF2RB frameshift on STAT5 activation 
in co-transfection studies  
Given the previously reported tolerizing effects of GM-CSF in the intestine, it would be 
predicted that the CD-associated frameshift mutation in CSF2RB would result in 
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decreased GM-CSF signaling21. Furthermore, the expected number of homozygotes 
was observed among CD cases, assuming Hardy-Weinberg equilibrium; namely, given 
the allele frequency estimate of 3.2% in CD cases, 3.1 CSF2RB frameshift 
homozygotes are predicted, with 4 cases observed. This general concordance is in 
contrast to the loss-of-function variants in NOD2, where a large excess of homozygous 
carriers are observed in CD cases. A prior report on the crystal structure of the ternary 
GM-CSF, CSF2RB, and the ligand-specific CSF2RA (colony-stimulating factor receptor, 
alpha chain) complex revealed an unexpected dodecamer, and possibly higher-order 
complex, with dodecamer assembly required for activation and signaling23. Both the 
genetic findings and crystal structure suggest a possible dominant negative loss-of-
function for the CSF2RB frameshift mutation.  
 
To directly assess this, we transfected CSF2RA with wild-type, mutant or equimolar 
amounts of wild-type and mutant forms of CSF2RB into HEK293 cells and stimulated 
cells with GM-CSF to assess signaling as measured by pSTAT5 expression (Figure 
4A). In five replicate experiments, we observed profoundly decreased pSTAT5 induction 
(0.16-fold, P value =  0.001) with mutant compared to wild-type CSF2RB. Importantly, 
we also observed a markedly lower pSTAT5 induction (0.38-fold, P value < 0.01) with 
wild-type plus mutant CSF2RB co-transfection compared to wild-type control (Figure 
4B). This would suggest that the mutant form of CSF2RB acts antagonistically to the 
wild-type allele.  
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Surface and intracellular levels of CSF2RB were similar for wild-type, mutant and wild-
type plus mutant CSF2RB transfectants (Figure 4C), such that the decrease in GM-
CSF-induced signaling was not attributable to decreased surface expression of mutant 
CSF2RB. Moreover, wild-type and mutant CSF2RB colocalized at the plasma 
membrane upon GM-CSF stimulation (Figure 4D). Collectively, these findings are 
consistent with a dominant negative effect of the CSF2RB frameshift mutation on GM-
CSF signaling. This would predict that heterozygous carriers, representing slightly over 
6% of AJ CD patients, would have impaired signaling with GM-CSF.  
 
Decreased STAT5 activation and aldehyde dehydrogenase induction in monocytes from 
CSF2RB frameshift carriers 
We next examined the functional effects of GM-CSF signaling in peripheral blood 
monocytes in wild-type and heterozygous carriers of the CSF2RB frameshift. 
Monocytes were serum starved overnight, then stimulated with 10, 2 and 0.4 ng/ml of 
GM-CSF for 15 minutes. Decreased pSTAT5 levels were observed in frameshift 
compared to wild-type monocytes (Figure 5A-B). In contrast, while robust induction of 
pERK and pAKT was observed with GM-CSF stimulation, no genotype-dependent 
differences were observed (Figure 5C-D).  
 
GM-CSF modulates mononuclear cell phagocyte differentiation broadly and its tolerizing 
effects within the intestine are mediated by retinoic acid21. Retinoic acid is produced 
from its precursor vitamin A (retinol) via the sequential actions of retinol dehydrogenase 
and aldehyde dehydrogenase enzymes. Aldehyde dehydrogenase activity is mediated 
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via multiple gene family members, and enzymatic activity was measured using the flow 
cytometry-based Aldefluor assay. Significantly greater Aldehyde dehydrogenase activity 
was observed in wild-type compared to CSF2RB frameshift monocyte-derived 
macrophages (Figure 5E-F), with highly consistent results observed in three paired 
replicates (Figure 5F).  
 
The central role of altered STAT5 activation in mediating pathogenic effects of the 
CSF2RB frameshift mutation is highlighted by both its predominant effect in intestinal 
signaling (Figure 3B) compared to pAKT and pERK, as well as the absence of 
genotype-dependent differences for the latter two pathways (Figure 5D). Prior studies 
have shown that GM-CSF signaling via dodecamer complex assembly enhances JAK2 
phosphorylation, which in turn phosphorylates multiple tyrosine residues of the CSF2RB 
cytoplasmic domain (Figure 6A-B) 23, 24. More proximal tyrosine residues (Tyr577, 
Tyr612, and Tyr695) of CSF2RB mediate MAP kinase24 and PI3kinase25 recruitment 
and activation, whereas more distal residues (Tyr612, Tyr695, Tyr750, and Tyr806) 
mediate STAT5 activation24, although functional overlap and redundancies have been 
reported26. Taken together, the present findings indicate that the pathogenic effects of 
the CD-associated CSF2RB frameshift mutation, which occurs at codon 708, resulting 
in truncation at codon 729, are significantly driven by impaired pSTAT5 activation.  
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Conclusions  
 
In this study, we have surveyed the role of uncommon frameshift mutations in 
Ashkenazi Jewish CD. For most common variants reported in GWAS, the genetic 
architecture among Ashkenazim is similar to non-Jewish European ancestry 
populations, with similar directions of risk alleles observed for the large majority of loci19. 
Rare variant analyses focused on Jewish populations may be particularly fruitful 
because of the higher CD prevalence and unique population history of the Ashkenazim. 
While the CSF2RB variant is most common in AJ populations, the similar trends and 
odds ratios observed in non-AJ populations indicates a more general role of impaired 
GM-CSF signaling in CD pathogenesis. Inferences on AJ population history based on 
whole genome sequencing suggest a reduction of population size, with a severe 
population bottleneck to as few as 350 individuals as recently as 28 thousand years 
ago27. This small founder population enables cataloguing of the vast majority of pre-
bottleneck AJ variation by sequencing a relatively modest number of individuals. This 
history would also suggest an increased power to detect variants of larger effect that 
drifted to higher frequencies during the bottleneck27. Sequencing 47 CD cases has 0.62, 
0.77 and 0.86 probabilities of observing variants of 1.0%, 1.5% and 2.0% frequency, 
respectively (Supplemental table 1), suggesting that we have tested a large fraction of 
the rare variants for which presently collected case-control cohorts are powered to 
detect association. Sequencing larger numbers of cases will identify successively rarer 
variants, some of which may have larger effect sizes, but will also require much larger 
cohort sizes to establish association (Supplemental table 1).  
 
A central value of genetic association studies is in defining primary pathogenic factors 
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driving disease expression. In CD, elevated levels of anti-GM-CSF autoantibodies are 
correlated with ileal location and worse clinical outcomes22. It is often unclear whether 
select autoantibodies observed in certain immune-mediated diseases are pathogenic, or 
merely reflect secondary effects of increased immune activity; the correlation of anti-
GM-CSF autoantibodies with more severe CD22 might merely reflect increased general 
immune activity in such cases. The present findings of a loss-of-function frameshift 
variant in CSF2RB argue for a primary pathogenic role of decreased GM-CSF signaling 
in driving a subset of CD cases. As many as 30% of CD cases have elevated levels of 
anti-GM-CSF antibodies, which can neutralize GM-CSF activity22, indicating that 
impaired GM-CSF signaling plays a major role in CD. These findings are consistent with 
a failure of the acute inflammatory response28. Pulmonary alveolar proteinosis is also 
associated with elevated auto-antibodies to GM-CSF, albeit at much higher titers than 
those observed in CD 22, 29. Of interest, a case of adult-onset pulmonary alveolar 
proteinosis was reported in an individual lacking anti-GMF-CSF autoantibodies, but 
instead carrying an autosomal recessive, single base pair deletion at nucleotide 631 of 
CSF2RB. This more proximal mutation was associated with the absence of surface 
expression of CSF2RB and the complete absence of GM-CSF induced signaling, in 
contrast to the hypomorphic effects of the CSF2RB mutation described here. Taken 
together, these findings highlight phenotypic variability resulting from variable degrees 
of impaired GM-CSF signaling. In addition, analyses of CSF2RA (CD116) expression in 
circulating granulocytes and monocytes demonstrated decreased expression of CD116 
as a distinguishing feature of IBD, broadly implicating impaired GM-CSF signaling in 
disease pathogenesis30.  
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Given the essential role of GM-CSF in maintaining intestinal tolerance21, the present 
association of a frameshift variant attenuating GM-CSF signaling and decreasing 
aldehyde dehydrogenase activity sharply contrasts CD pathogenesis from rheumatoid 
arthritis, where anti-GM-CSF monoclonal antibodies have demonstrated efficacy31. 
While a meta-analysis of three studies involving GM-CSF administration did not 
establish superiority of treatment in CD, all studies showed a trend toward efficacy32; it 
is possible that future studies may identify subsets of CD patients for which agonism of 
the GM-CSF pathway is most effective.  
 
The correlation of GM-CSF autoantibodies in complicated CD(**REF) strongly 
implicates decreased GM-CSF signaling in the pathogenesis of the CSF2RB frameshift 
mutation. However, given the high expression of CSF2RB on intestinal eosinophils 
(Figure 2A), future studies exploring the comparative effects of IL-3 and IL-5 on altered 
eosinophil differentiation and function would provide additional insight. In addition, 
because GM-CSF-deficient mice demonstrated impaired epithelial proliferation and 
ulcer healing in response to DSS-induced injury(PMID: 23325885), future studies 
examining the effects of the CSF2RB mutation on altered epithelial cell function would 
potentially highlight additional contributing disease mechanisms.  
 
Given the prior associations of loss-of-function risk alleles involving the NOD24 and 
autophagy innate immune pathways33, 34 the present identification of a loss-of-function 
CSF2RB frameshift mutation highlights the multiple innate immune deficiencies 
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associated with CD. In further support of this, patients with chronic granulomatous 
disease, characterized by phagocytic defects, can present with intestinal inflammation35. 
While the present major therapies involve general immunosuppression, if CD is, in a 
subset of patients, a primary immunodeficiency of macrophages36, a fundamental 
paradigm shift may be in order; enhancing specific phagocyte cell subset function may 
be a more effective means of developing the novel therapies needed in CD.  
 
Supplementary Materials 
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Figure legends  
 
Figure 1. Frameshift mutation in CSF2RB associated to CD. A) Quantile-quantile 
plot of 88 frameshift mutations in the CD case-control discovery cohort (1477 cases, 
2614 controls).  B) Schematic of wild-type (WT) and frameshift-containing (Mut) 
CSF2RB transcript, with fibronectin type III (FN3) domains indicated in pink, and altered 
frameshift region prior to stop codon indicated in red. 
   
 
Figure 2. CyTOF analysis of cellular expression of CSF2RB, CSF2RA, NOD2 and 
CD206 in CD intestine. Representative cluster plot of CyTOF output for not inflamed 
(left) and inflamed (right) regions from resected terminal ileum from a CD patient. Colors 
correspond to the average quantity of CSF2RB (A), CSF2RA (B), NOD2 (C) and CD206 
(D) detected per cell (blue to red continuum corresponding with low to high expression). 
The size of each node corresponds to the number of individual cells detected.   
 
Figure 3. CyTOF analysis of intestinal cells from CD patients defines GM-CSF 
responding cell subsets. (A) Summary of proportions of immune cell subtypes 
detected in not-inflamed and inflamed ileal specimens (n=3). (B) Relative quantities of 
receptor subunits (left) and intracellular signaling molecules (right) by immune cell 
subtype in both inflamed (right) (n=3) and not inflamed (left) regions of resected terminal 
ileum. (C) Quantification of CSF2RA (green) and CSF2RB (orange) expression in 
immune cell subsets. (D) Fold-change of phosphorylated STAT5 in immune cell subsets 
in response to GM-CSF treatment in inflamed (red) and not inflamed (blue) ileal 
samples. Significance estimates in (D) are compared to no GM-CSF treatment. *, P < 
.05. 
 
Figure 4. The CD-associated frameshift in CSF2RB results in a truncated protein 
and attenuates GM-CSF-induced STAT5 phosphorylation in a dominant negative 
manner. (A) HEK293 cells were transfected with CSF2RA + wild-type (WT) and/or 
frameshift mutation (Mut) CSF2RB, alone or in combination.  Cells were then treated 
with 10ng/ml GM-CSF for 15min. Representative western blot displaying products of 
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transfection and phospho-STAT5. STAT5 and β-actin are shown as loading controls. 
(B) Quantitative levels of pSTAT5 relative to wild-type control (CSF2RB_WT) from five 
replicated experiments. **, P < .01. (C) Transfected HEK293 cells were stained with 
isotype antibodies (black line) or anti-CSF2RB antibodies (red line) on their surface (top 
row) and intracellularly (bottom row). Representative histograms are shown. (D) 
Confocal fluorescent micrograph illustrating intracellular localization of wild-type (left), 
mutant (middle) construct products and merge (right) in cells co-transfected with both 
constructs with 10ng/ml GM-CSF treatment for 15min. Yellow areas indicate the co-
localization of CSF2RB_WT and CSF2RB_Mut receptors. Scale bar: 5µm. 
 
Figure 5. Primary monocytes from CSF2RB frameshift carriers demonstrate 
diminished GM-CSF mediated pSTAT5 and aldehyde dehydrogenase activity with 
intact ERK and AKT activation. (A) Representative immunoblot of peripheral 
monocytes from a CSF2RB frameshift carrier and matched control displaying pSTAT5 
and total STAT5 15 min after stimulation with various concentrations of GM-CSF. (B) 
Quantification of pSTAT5 levels after GM-CSF stimulation in three phenotypically 
matched pairs with normalizing to loading control. *, P < .05. (C) Immunoblot of pERK 
and pAKT in a frameshift carrier and a matched non-carrier after GM-CSF stimulation. 
(D) Quantification of pERK and pAKT in 3 matched pairs of frameshift carriers and non-
carriers. (E) Activity of aldehyde dehydrogenase (ALDH), an enzymatic catalyst involved 
in retinoic acid synthesis, as measured by flow cytometry detecting ALDEFLUOR after 
10ng/ml of GM-CSF stimulation for 15 minutes, in a CSF2RB frameshift non-carrier 
(top) and a matched carrier (middle). (F) Quantification of ALDH activity by mean 
ALDEFLUOR intensity in 3 pairs of frameshift carriers and non-carriers. **, P < .01.  
  
Figure 6. Schematic model of altered GM-CSF signaling with the CSF2RB 
frameshift mutation. GM-CSF signaling includes GM-CSF cytokine (green), CSF2RA 
(yellow) and CSF2RB (wild-type in blue, mutant in pink) components. Crystal structure 
analysis reveals a high affinity, hexameric bridge. JAK2, associated with the CSF2RB 
cytoplasmic domain, is able to dimerize and transphosphorylate in the dodecamer, but 
not in the hexamer complex. With GM-CSF stimulation of wild-type CSF2RB (A, blue), 
potent induction of pSTAT5, pAKT, and pERK is observed. However, with heterozygous 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CSF2RB frameshift carriage (wild-type in blue, mutant in pink CSF2RB with the 
frameshift region in red) pAKT and pERK signaling is largely intact, reflecting interaction 
with more proximal tyrosine residues within the CSF2RB tail. In contrast, JAK2 interacts 
with more distal tyrosine residues within CSF2RB. Given the JAK2 requirement for 
dimerization and transphophorylation in the dodecamer complex, the CSF2RB 
frameshift mutation would impair wild-type CSF2RB signaling, consistent with results 
observed in both cellular transfectant (Figure 4) and primary monocyte (Figure 5) 
studies.  
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Table 1. Association results for the CSF2RB frameshift mutation  
MAF, minor allele frequency; OR, odds ratio  
 
 
NCD Nctrl MAFCD MAFctrl P value OR 
AJ Discovery cohort  1477 2614 0.032 0.020 8.52x10-4 1.6 
AJ Replication cohort 1515 7052 0.033 0.022 5.39x10-4 1.5 
Total 2992 9666 0.032 0.022 3.42x10-6 1.5 
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Cohort Ntotal NCD cases
NIDDK IBD Genetic Consortium 412 323
Mount Sinai School of Medicine 403 352
Yale University 268 268
Cedars Sinai Medical Center 791 384
University of Miami 96 96
University of Toronto 35 29
CCFA Pediatric IBD Consortium 16 16
Feinstein Institute for Medical Research 321 -
Hebrew University of Jerusalem 1579 -
Albert Einstein College of Medicine 86 -
University of Pittsburgh 72 -
Other 12 9
Total 4650 1477
Cohort Ntotal NCD cases
NIDDK IBD Genetic Consortium 2046 1097
Mount Sinai School of Medicine 976 272
University College London 194 194
Ashkenazi Genomic Consortium 128 -
Hebrew University Genetic Resource 5291* -
Total 8473* (3344) 1563
* Genotyped only at CSF2RB  frameshift
704
-
128
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-
6
-
321
1579
86
72
3
2614
Replication
Ncontrols
407
Discovery
Ncontrols
89
51
-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0.0001 0.001 0.005 0.01 0.015 0.02 0.025 0.03 0.04 0.05 0.1
0.01 0.09 0.39 0.62 0.77 0.86 0.91 0.95 0.98 0.99 1
Odds ratio
0.33 0 0.12 0.92 1 1 1 1 1 1 1 1
0.4 0 0.05 0.66 0.97 1 1 1 1 1 1 1
0.5 0 0.02 0.25 0.65 0.89 0.97 0.99 1 1 1 1
0.66 0 0 0.03 0.11 0.21 0.33 0.46 0.57 0.76 0.87 1
0.9 0 0 0 0 0 0 0.01 0.01 0.01 0.01 0.03
1.1 0 0 0 0 0 0 0 0 0.01 0.01 0.02
1.5 0 0 0.01 0.04 0.08 0.13 0.19 0.26 0.41 0.55 0.93
2 0 0.01 0.06 0.19 0.36 0.54 0.69 0.8 0.93 0.98 1
2.5 0 0.01 0.11 0.36 0.62 0.81 0.91 0.96 1 1 1
3 0 0.01 0.17 0.51 0.78 0.92 0.98 0.99 1 1 1
0% power to detect significant association 100% power to detect significant association
Minor allele frequency (MAF) in case samples
Estimated power to detect a variant in sequencing of 94 independent chromosomes, by MAF
Estimated Power to Detect Significance (α=0.001) of Single Markers in 1477 Cases and 2614 Controls, by MAF
0% power to observe variant 100% power to observe variant
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139 La FceR1a
141 Pr CD45
142 Nd CD19
143 Nd Biotin-LRRK2
144 Nd CD141
145 Nd CD4
146 Nd CD8
147 Sm Nod2
148 Nd CD16
149 Sm CD66
150 Nd pSTAT5
151 Eu CD123
152 Sm pAkt
153 Eu CD1c
154 Sm CD163
156 Gd p38
158 Gd pSTAT3
159 Tb CD11c
160 Gd CD14
162 Dy CD32
164 Dy IkBa
165 Ho CD116
166 Er CD24
167 Er CD38
168 Er CD206
169 Tm CD131
170 Er CD3
171 Yb ERK1/2
173 Yb CD56
174 Yb HLADR
175 Lu pS6
191/193Ir Ir-intercalator
195Pt Cisplatin
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Supplemental Figure 1. Principal components analysis defines Ashkenazi Jewish 
cohort. We created a set of 10,312 null independent autosomal polymorphisms by 
removing markers with pairwise linkage disequilibrium (LD) of r2 > 0.05, those with 
minor allele frequency (MAF) below 0.05. Principal components was performed using 
the princomp() function in R version 2.15.1. The PCA was conducted on our dataset in 
conjunction with a reference cohort comprising currently unpublished, non-Jewish 
European-ancestry samples on which exome chip data was available. Boundaries 
defined along the top three principal components were used to define outlier samples 
for removal from the AJ cohort. We determined that many of the excluded samples had 
self-reported less than 100% AJ ancestry. No significant correlations between the top 
principal components and case-control status, geographic location, or genotyping center 
were observed. Using membership in the PCA cluster as genetic validation of AJ 
ancestry, we conducted all further analyses using only samples with 100% AJ ancestry: 
1,477 CD cases, 559 UC cases, and 2,614 independent healthy controls (Table S1). 
 
Supplemental Figure 2. Comparative analysis of Cytof and phospho flow 
cytometry. Fold induction of pSTAT5, pAKT, and pERK as calculated by Cytof (A) and 
phospho flow cytometry (B) of three replicates for each technique, examining intestinal 
resection tissues from a total of six CD patients. *, P value < 0.05. C. Representative 
flow cytometry comparing unstimulated and GM-CSF stimulated pSTAT5 in CD14+ 
cells.  
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